Treatment strategies for therapy-related acute myeloid leukemia
Prospective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and therapy-specific factors. Clinical trials are recommended, especially for unfit patients or those with unfavorable cytogenetics or mutations. CPX-351 as an upfront intensive chemotherapy is preferred for fit patients; venetoclax with decitabine or azacitidine is an option for patients unfit for intensive chemotherapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Prajwal Dhakal, Bimatshu Pyakuryal, Prasun Pudasainee, Venkat Rajasurya, Krishna Gundabolu, Vijaya Raj Bhatt Tags: Review Article Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma